Damora Therapeutics (DMRA) Capital Expenditures (2021 - 2022)
Damora Therapeutics (DMRA) reported Capital Expenditures of $41000.0 for Q4 2022, up 1125.0% on a YoY basis from $3346.9 in Q4 2021, and down 70.29% quarter-over-quarter from $138000.0 in Q3 2022.
Damora Therapeutics (DMRA) Capital Expenditures (2021 - 2022) Analysis & Trends
Damora Therapeutics has reported Capital Expenditures for 2 years, with the latest figure at $41000.0 in Q4 2022.
- For the quarter ending Q4 2022, Capital Expenditures rose 1125.0% year-over-year to $41000.0; the trailing twelve-month figure through Dec 2022 stood at $196000.0 (down 12.11% YoY), and the FY2022 full-year result was $196000.0, down 12.11% from the prior year.
- Capital Expenditures for Q4 2022 stood at $41000.0, down from $138000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $138000.0 in Q3 2022, with the low at -$26000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 41,000.00 |
| Dec 31, 2022 | 41,000.00 |
| Sep 30, 2022 | 138,000.00 |
| Sep 30, 2022 | 138,000.00 |
| Jun 30, 2022 | -26,000.00 |
| Jun 30, 2022 | -26,000.00 |
| Mar 31, 2022 | 43,000.00 |
| Mar 31, 2022 | 43,000.00 |
| Dec 31, 2021 | -4,000.00 |
| Dec 31, 2021 | -4,000.00 |
| Sep 30, 2021 | 47,000.00 |
| Sep 30, 2021 | 47,000.00 |
| Jun 30, 2021 | 115,000.00 |
| Jun 30, 2021 | 115,000.00 |
| Mar 31, 2021 | 65,000.00 |
| Mar 31, 2021 | 65,000.00 |